Market Cap 603.73M
Revenue (ttm) 99.60M
Net Income (ttm) 8.55M
EPS (ttm) N/A
PE Ratio 57.08
Forward PE 58.58
Profit Margin 8.58%
Debt to Equity Ratio 0.00
Volume 667,000
Avg Vol 1,035,844
Day's Range N/A - N/A
Shares Out 79.75M
Stochastic %K 62%
Beta 2.13
Analysts Strong Sell
Price Target $15.55

Company Profile

Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+) test kits to healthcare practitioners; and develops and commercializes proprietary-based ingredient...

Industry: Biotechnology
Sector: Healthcare
Phone: 310 388 6706
Address:
10900 Wilshire Blvd, Suite 600, Los Angeles, United States
CarpSlayer
CarpSlayer Oct. 25 at 3:23 PM
$NAGE - NAD+ market analysis: From hype to reality check 23-Oct-2025 by Afif Ghannoum, CEO, CPG Radar This article is paywalled. The description sounds counter intuitive to what we are seeing on the consumer side with Tru Niagen posting seven consecutive quarters of sequential revenue growth. "The NAD+ supplement market is experiencing a dramatic transformation that reveals a fundamental shift in consumer behavior. While scientific curiosity about NAD+ has surged 133% since early 2024, actual purchase intent has collapsed by nearly half." https://www.nutraingredients.com/Article/2025/10/23/nad-market-analysis-from-hype-to-reality-check/
1 · Reply
Jimgym
Jimgym Oct. 25 at 1:30 AM
$NAGE short interest shot right back up another +420k shares to 4,172,117 as of Oct 15. I guess we know why the drop after the FDA allowed NMN was so exaggerated
1 · Reply
CarpSlayer
CarpSlayer Oct. 24 at 3:57 PM
$NAGE - NAD⁺: The longevity molecule transforming functional food and drinkOpens in new window 23-Oct-2025 by Donna Eastlake NAD⁺ is emerging as a key ingredient in the longevity space. Discover the science, product potential, and formulation challenges shaping this fast-growing category https://www.foodnavigator.com/Article/2025/10/23/nad-the-longevity-molecule-transforming-functional-food-and-drink/
2 · Reply
Smorea
Smorea Oct. 24 at 2:54 PM
$NAGE looks to be approaching a long term squeeze! 1 or 2 more days then straight up!
2 · Reply
wycliff
wycliff Oct. 24 at 1:08 PM
$NAGE https://www.nutraingredients.com/Article/2025/10/23/nad-market-analysis-from-hype-to-reality-check/
1 · Reply
wycliff
wycliff Oct. 24 at 8:14 AM
$NAGE https://www.linkedin.com/posts/activity-7387355428025950208-kq4c?utm_source=share&utm_medium=member_ios&rcm=ACoAAAUGerIBOiyuZoO-6U9HRKRzZ48AD8YnjZA
0 · Reply
wycliff
wycliff Oct. 24 at 12:12 AM
$NAGE https://gemini.google.com/share/39e5082271f9
0 · Reply
wycliff
wycliff Oct. 24 at 12:11 AM
$NAGE https://g.co/gemini/share/39e5082271f9
0 · Reply
MattManzanita
MattManzanita Oct. 23 at 8:46 PM
$NAGE have beaten this horse before, but I am still wondering what is going on with the Northwestern University peripheral artery disease trial. As you may recall, the trial is identified as being at Phase 3 on clinicaltrials.gov, that it was first published in Nature about 16 months ago, and that the results using NR showed improvement in this condition that affects between 8 million and 21 million (quite a range...) in the US, for which there are no good established drug remedies. They used 2000 mg in the trial. Given the number of people who suffer from the condition, the dose used in the trial, and that the FDA classifies PAD as a disease, the potential is perhaps greater than that for Long COVID and Parkinson's disease combined. The lead researcher has said that another larger trial needs to be conducted. That in itself does not mean that FDA accelerated approval might not be sought.
1 · Reply
theflynews
theflynews Oct. 23 at 6:17 PM
Meet Niagen Bioscience: Fly exclusive interview with CFO Ozan Pamir - $NAGE - https://thefly.com/permalinks/entry.php/NAGEid4219895?1761242
0 · Reply
Latest News on NAGE
Niagen Bioscience: High Conviction, High Expectations

Jun 11, 2025, 6:48 AM EDT - 4 months ago

Niagen Bioscience: High Conviction, High Expectations


Niagen Bioscience, Inc. (NAGE) Q1 202 Earnings Call Transcript

May 10, 2025, 1:40 PM EDT - 6 months ago

Niagen Bioscience, Inc. (NAGE) Q1 202 Earnings Call Transcript


ChromaDex to Present at the 37th Annual Roth Conference

Mar 11, 2025, 4:04 PM EDT - 8 months ago

ChromaDex to Present at the 37th Annual Roth Conference


ChromaDex Corporation (CDXC) Q4 2024 Earnings Call Transcript

Mar 4, 2025, 8:53 PM EST - 8 months ago

ChromaDex Corporation (CDXC) Q4 2024 Earnings Call Transcript


ChromaDex Appoints Ozan Pamir as Chief Financial Officer

Sep 20, 2024, 8:32 AM EDT - 1 year ago

ChromaDex Appoints Ozan Pamir as Chief Financial Officer


CarpSlayer
CarpSlayer Oct. 25 at 3:23 PM
$NAGE - NAD+ market analysis: From hype to reality check 23-Oct-2025 by Afif Ghannoum, CEO, CPG Radar This article is paywalled. The description sounds counter intuitive to what we are seeing on the consumer side with Tru Niagen posting seven consecutive quarters of sequential revenue growth. "The NAD+ supplement market is experiencing a dramatic transformation that reveals a fundamental shift in consumer behavior. While scientific curiosity about NAD+ has surged 133% since early 2024, actual purchase intent has collapsed by nearly half." https://www.nutraingredients.com/Article/2025/10/23/nad-market-analysis-from-hype-to-reality-check/
1 · Reply
Jimgym
Jimgym Oct. 25 at 1:30 AM
$NAGE short interest shot right back up another +420k shares to 4,172,117 as of Oct 15. I guess we know why the drop after the FDA allowed NMN was so exaggerated
1 · Reply
CarpSlayer
CarpSlayer Oct. 24 at 3:57 PM
$NAGE - NAD⁺: The longevity molecule transforming functional food and drinkOpens in new window 23-Oct-2025 by Donna Eastlake NAD⁺ is emerging as a key ingredient in the longevity space. Discover the science, product potential, and formulation challenges shaping this fast-growing category https://www.foodnavigator.com/Article/2025/10/23/nad-the-longevity-molecule-transforming-functional-food-and-drink/
2 · Reply
Smorea
Smorea Oct. 24 at 2:54 PM
$NAGE looks to be approaching a long term squeeze! 1 or 2 more days then straight up!
2 · Reply
wycliff
wycliff Oct. 24 at 1:08 PM
$NAGE https://www.nutraingredients.com/Article/2025/10/23/nad-market-analysis-from-hype-to-reality-check/
1 · Reply
wycliff
wycliff Oct. 24 at 8:14 AM
$NAGE https://www.linkedin.com/posts/activity-7387355428025950208-kq4c?utm_source=share&utm_medium=member_ios&rcm=ACoAAAUGerIBOiyuZoO-6U9HRKRzZ48AD8YnjZA
0 · Reply
wycliff
wycliff Oct. 24 at 12:12 AM
$NAGE https://gemini.google.com/share/39e5082271f9
0 · Reply
wycliff
wycliff Oct. 24 at 12:11 AM
$NAGE https://g.co/gemini/share/39e5082271f9
0 · Reply
MattManzanita
MattManzanita Oct. 23 at 8:46 PM
$NAGE have beaten this horse before, but I am still wondering what is going on with the Northwestern University peripheral artery disease trial. As you may recall, the trial is identified as being at Phase 3 on clinicaltrials.gov, that it was first published in Nature about 16 months ago, and that the results using NR showed improvement in this condition that affects between 8 million and 21 million (quite a range...) in the US, for which there are no good established drug remedies. They used 2000 mg in the trial. Given the number of people who suffer from the condition, the dose used in the trial, and that the FDA classifies PAD as a disease, the potential is perhaps greater than that for Long COVID and Parkinson's disease combined. The lead researcher has said that another larger trial needs to be conducted. That in itself does not mean that FDA accelerated approval might not be sought.
1 · Reply
theflynews
theflynews Oct. 23 at 6:17 PM
Meet Niagen Bioscience: Fly exclusive interview with CFO Ozan Pamir - $NAGE - https://thefly.com/permalinks/entry.php/NAGEid4219895?1761242
0 · Reply
SS_67
SS_67 Oct. 23 at 1:28 PM
$NAGE Boosting longevity NAD+ https://www.nytimes.com/2025/10/23/well/nad-boosting-longevity.html
0 · Reply
wycliff
wycliff Oct. 23 at 12:50 PM
$NAGE https://www.supplysidesj.com/supplement-regulations/niagen-bioscience-scores-partial-win-in-advertising-challenge
1 · Reply
wycliff
wycliff Oct. 23 at 12:49 PM
$NAGE https://www.linkedin.com/posts/activity-7387081753276100608-D5PI?utm_source=share&utm_medium=member_ios&rcm=ACoAAAUGerIBOiyuZoO-6U9HRKRzZ48AD8YnjZA
0 · Reply
tymtested
tymtested Oct. 23 at 11:55 AM
$NAGE very attractively priced!
0 · Reply
okeydokey_artichokey
okeydokey_artichokey Oct. 22 at 10:02 PM
$NAGE With "everything " going on, plus a certain health Sec., we can be thankful for a retail product.
0 · Reply
BenTheDo
BenTheDo Oct. 22 at 4:52 PM
$NAGE you all doubted my 4 PT in the summer and look where we are now!
0 · Reply
BenTheDo
BenTheDo Oct. 22 at 4:52 PM
0 · Reply
CarpSlayer
CarpSlayer Oct. 22 at 2:05 PM
$NAGE The therapeutic effect of nicotinamide riboside chloride on ameliorating alcohol-induced neuronal damage with a focus on mitochondrial unfolded protein response and mitophagy Chinese mice study. https://www.sciencedirect.com/science/article/pii/S2352304225003757
0 · Reply
tymtested
tymtested Oct. 21 at 10:04 PM
$NAGE since its going to $100 ,I better buy more shares.
0 · Reply
CarpSlayer
CarpSlayer Oct. 21 at 3:46 PM
$NAGE NAD-RBD, a Phase III multi-centre, randomised, double-blind, placebo-controlled study, will evaluate the efficacy of NAD-replenishment therapy in halting the progression of motor and cognitive dysfunction in individuals with iRBD. We plan to enrol 400 participants across 11 centres in Norway and treat them for 24–58 months The primary objective of the project is to assess the clinical efficacy of NR in delaying the progression of motor dysfunction, cognitive dysfunction, or phenoconversion in individuals with iRBD. Status: The protocol has been established. Recruitment is planned for Q4 2025. Post NoPark startup Trials, (completion Q2 2025) where the results are known to the research team at this point, may suggest that NR showed a meaningful benefit in NoPark or why continue with NR in a new Phase III if NoPark was a fail? TBD of course. https://www.helse-bergen.no/en/neuro-sysmed-english/clinical-studies-at-neuro-sysmed/parkinsons--clinical-studies/nad-rbd/
3 · Reply
wycliff
wycliff Oct. 21 at 12:37 PM
$NAGE https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fevents.q4inc.com%2Fattendee%2F223363783&esheet=54341686&newsitemid=20251021852088&lan=en-US&anchor=Niagen+Bioscience+Third+Quarter+2025+Earnings+Conference+Call&index=2&md5=1ef967b56893daf684bb1d5d057a4ae1
0 · Reply
stupidusername
stupidusername Oct. 20 at 7:38 PM
$NAGE https://x.com/huwithdrdrew/status/1978494227064500472?s=46&t=jwUh-RtE9NQT7uLrU59Zdg
1 · Reply